How Society's 'Man Up' Mentality Is Impacting Mental Health Of Young Men
Toxic masculinity isn't just a societal stereotype—it's a harmful set of expectations that dictate how men should behave, often at the cost of their mental health. The pressure to conform to these outdated ideals forces men to suppress emotions, chase unrealistic goals, and develop unhealthy coping mechanisms. This International Men’s Day, it's time we rethink the narrative and focus on healthier ways to define masculinity.
At just 12 years old, my cousin Aryan already faced the weight of societal expectations he couldn’t fully understand. One afternoon, after scraping his knee during a football game, he burst into tears. His coach immediately scolded him, "Be a man! Men don’t cry. Toughen up, it’s just a part of the game." Aryan quickly wiped his tears, eager to avoid being labeled as weak in front of his friends.
Later that day, while his mother was preparing dinner, Aryan, fascinated by the process, got up to flip the roti. From across the room, his father, without hesitation, remarked, “You’re a man now, no need to be in the kitchen. Come sit and relax with me.”
These experiences, though seemingly small, are part of the broader societal conditioning that teaches boys from a young age to equate masculinity with emotional suppression, dominance, and emotional unavailability. This is the very essence of what psychologists identify as toxic masculinity—a set of cultural norms that encourage men to ignore their emotional needs, often leading to long-term mental health struggles.
From an early age, boys are taught that emotions like sadness or vulnerability are signs of weakness. According to Bobby Thakur, a psychologist at Counsel India, phrases like "man up" and "boys don’t cry" perpetuate the idea that expressing emotions is unacceptable. As these young boys grow into adults, they are burdened with an overwhelming need to meet unrealistic standards of success, whether it be in their careers, physical appearance, or social standing.
Thakur explains, "Young men often feel trapped. They are pressured to excel in every aspect of life, which leads to emotional isolation, stress, and a higher risk of mental health issues." The pressure to be stoic and unfeeling can be devastating. As boys grow into men, the inability to express their emotions healthily often leads to anxiety, depression, and heightened levels of aggression.
When emotions are constantly suppressed, young men often struggle to find healthy outlets for their stress, leading to a vicious cycle of negative coping mechanisms. Thakur notes that this emotional repression can result in mental health issues such as depression and anxiety, and in some cases, substance abuse. Many young men turn to alcohol or drugs to numb the emotional pain they feel but are unable to express.
The stigma surrounding mental health in men exacerbates these struggles. "In a culture where vulnerability is seen as a weakness, many young men are reluctant to seek help until their problems have spiraled out of control," Thakur adds. The lack of emotional support and the belief that seeking help is a sign of failure only deepens the isolation men face when dealing with mental health challenges.
One of the biggest societal challenges is the constant reinforcement of the 'man up' mentality. From media portrayals of muscular, emotionally stoic men to the glorification of power and success, society has created an unrealistic and damaging image of what it means to be a man. These ideals can leave young men feeling inadequate, emotionally exhausted, and ultimately disconnected from their true selves.
Boys are taught that success is about being dominant and in control, which leaves little room for emotional expression. As a result, they feel pressured to meet unattainable standards, leading to feelings of anxiety, depression, and isolation. These mental health issues often remain unaddressed because vulnerability is stigmatized.
Bobby Thakur emphasizes that the current narrative around masculinity needs to evolve. "True strength lies in emotional intelligence, self-awareness, and the courage to seek help when needed." To create a healthier future for young men, society must prioritize open discussions about mental health and encourage emotional expression.
Here are some ways to foster a healthier understanding of masculinity and mental health:
1. Encourage boys to share their emotions without the fear of judgment or ridicule.
2. Teach young men the value of understanding and managing their emotions.
3. Use media and education to dismantle the glorification of toxic masculine traits.
4. Create a supportive environment where seeking therapy and mental health resources is seen as a strength, not a weakness.
As Thakur puts it, "The true measure of masculinity is not in the suppression of emotions but in the courage to embrace them authentically." Changing the narrative around masculinity is critical to ensuring the mental well-being of future generations. By fostering an environment where young men can openly discuss their struggles and embrace emotional vulnerability, we can break the cycle of toxic masculinity and its harmful impact on mental health.
Credit: iStock
GLP-1 drugs are powerful tools that can improve health, but it comes with risks and caveats. While these are medical therapies, they are being misused as cosmetic products by cosmetologists, physiotherapists, dermatologists, among others.
To curb its misuse and improve public health, the Indian government today issued guidelines on its use, while also flagging risks around it.
In an official statement issued today, the government has stated that it will roll out stricter inspections to curb the misuse of GLP-1 drugs in the country and will punish those who violate the rules.
“GLP-1 drugs are a significant medical breakthrough in treating type 2 diabetes and obesity, but they are not without risk. The drugs carry a wide range of side effects - from common symptoms like nausea and vomiting to severe complications including pancreatitis, kidney injury, and bowel obstruction. These risks make it essential that GLP-1 drugs are only taken under the supervision of registered medical practitioners/specialists,” the statement said.
In the wake of its hype over weight loss, the country's regulatory authorities have taken firm steps to prevent unsupervised use and malpractices in the supply chain.
It has “strongly advised” patients and the public to” consult a qualified medical specialist before use, and to obtain these medications with prescription only through legitimate, regulated channels”.
“Stricter inspections and surveillance will continue in the coming weeks. Businesses that break the rules will face license cancellation, fines, and legal action,” the statement said.
Also read: GLP-1 Drugs: Why India Needs Stricter Rules Now
GLP-1 drugs work to keep food in the digestive system for longer – making people feel fuller for longer, thus reducing appetite and inducing weight loss. Hence, the drugs are also prescribed to people with obesity.
However, when done without clinical oversight, it can lead to severe health complications.

There are various side effects to taking GLP-1 drugs, including nausea and dizziness, to pancreatitis and medullary thyroid cancer.
Some serious side effects include

GLP-1 medications may also complicate various health conditions, such as allergic reactions, with shortness of breath and low blood sugar.
The government's advisory comes as patent for semaglutide -- an active ingredient in diabetes and anti-obesity drugs, specifically Wegovy and Ozempic -- expired on March 20.
This has led to a rush among Indian pharma companies to launch cheaper generic versions, significantly increasing affordability and access for millions battling Type 2 diabetes and obesity.
Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs
Major Indian drugmakers who launched their generic semglutide injection in the country in March include Sun Pharmaceutical Industries, Zydus Lifesciences, Alkem Laboratories, and Dr. Reddy’s Laboratories.
Amid the increasing prevalence of GLP-1 drugs, the World Health Organisation (WHO), late last year, acknowledged its role in treating obesity.
However, it warned that medications like GLP-1 alone will not solve the problem affecting more than one billion people worldwide.
The global health body also issued conditional recommendations for using these therapies as part of a comprehensive approach that includes healthy diets, regular physical activity, and support from health professionals.
Credit: iStock
Danish pharma giant Novo Nordisk has once again reduced the prices of its blockbuster drugs Ozempic and Wegovy in India. The strategic move is aimed at staying ahead of the entry of the low-cost generic competition in the country.
Starting today, the Ozempic price in India will be cut by 36 percent, while Wegovy has seen a steeper 48 percent reduction — limiting the base price below Rs 6,000 per month.
While Ozempic is available in three dose strengths of 0.25 mg, 0.5 mg, and 1 mg in India, Wegovy has five dose strengths.
Ozempic's and Wegovy's lowest doses of 0.25 mg will now be priced at Rs 1,415 for a weekly shot from Rs 2,200 and Rs 2,712 earlier, respectively, Novo Nordisk India said in a statement on Tuesday.
The average price reduction across doses is 23.8 percent for Ozempic and 27 percent for Wegovy, it added.
Speaking to the media, Novo Nordisk stated that the price cut will benefit a large section of people with diabetes and obesity in India.
The generic weight loss drugs will open up a huge customer base, especially in India, with a high burden of diabetes and obesity.
Novo first slashed Wegovy's price for the first time by up to 37 percent from its launch price last year.
In addition to the entry of generics, the launch of rival Eli Lilly's blockbuster diabetes and obesity drug Mounjaro in India in 2025.
Also read: Semaglutide Becomes Cheap In India: A Gamechanger Or Health Gamble?
Soon after the end of Novo Nordisk's patent on semaglutide, on March 20, a host of companies in India launched generic versions of Ozempic.
This includes NATCO Pharma's Semanat and Semafull, priced at Rs 1,290 per month and Rs 1,750 — about 90 per cent cheaper than Ozempic, costing Rs 8,800 per month.
Eris Lifesciences also announced its plans to launch a multi-dose vial under the brand name Sundae at the same price.
Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Glenmark Pharmaceuticals have also launched their generic versions of semaglutide.
Dr. Reddy’s Obeda is priced at Rs 4,200 per month, available in 2 mg and 4 mg strengths.
Sun Pharmaceutical Industries will sell under the brand names Noveltreat (doses ranging from Rs 900) and Sematrinity (doses ranging from Rs 750). Meanwhile, Glenmark’s GLIPIQ vials range from Rs 325 to Rs 440 per week.
Zydus Lifesciences has also announced the launch of its generic version of semaglutide injection under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMET. The average monthly cost of the treatment will be about Rs 2,200, the company said in a statement.
Semaglutide works as a GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate appetite and blood sugar. It slows gastric emptying and makes you feel fuller longer. It also signals the brain to reduce hunger and cravings, and triggers the pancreas to release insulin when blood sugar is high.
Also read: This Pill Is More Effective For Weight Loss Than Ozempic, Scientists Say
They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.
In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and the body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of another hormone called glucagon.
These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.
Credit: iStock
Health officials in the US have issued a risk of leptospirosis — a bacterial illness — in Hawaii, after the “Kona low” storm floods.
The Hawaii Department of Health (DOH) and the Hawaiian Humane Society (HHS) have urged residents and recovery workers to monitor for signs of leptospirosis that can affect both people and pets.
Leptospirosis is caused by bacteria Leptospira, which are carried in the urine of infected animals, including rats, mice, mongoose, livestock, and dogs.
The disease can spread via the urine of infected animals and can enter the human body through broken skin or through the mouth, nose, or eyes.
“Hawaii already has among the highest rates of leptospirosis in the country due to its warm, wet climate,” said HHS and DOH in a joint statement.
“Flooding events like the recent Kona low storm can dramatically increase exposure risk by spreading contaminated soil and water across a broad area,” it added.
The agency urged people to check out symptoms in pets, such as fever, decreased appetite, vomiting, diarrhea, and muscle soreness, and get medical help.
The risk of Leptospirosis outbreak is common after a storm, because the dead animals are likely to spread the bacteria. Further, flooding also forces rodents out of their burrows, leading them into homes, shelters, and debris piles where they shed bacteria more easily.
Leptospirosis is one of the most prevalent zoonotic diseases worldwide, often linked to poor sanitation and agricultural practices that involve contact with animals or contaminated water.
The bacteria can survive in contaminated water or soil for weeks to months, primarily spreading through the urine of infected animals.
Humans can contract the disease through direct contact with infected urine or through contaminated food, water, or soil.
There are two main forms of leptospirosis: icteric leptospira, which presents with jaundice, and anicteric leptospira, a milder variant without jaundice. Leptospirosis can also manifest as Weil's disease, a severe complication.
Symptoms typically develop 2 to 30 days after exposure and can range from mild to severe. Initial signs often include
In more serious cases, the infection can lead to complications such as
Pulmonary hemorrhage — acute bleeding from the lungs — can also occur, posing life-threatening risks such as respiratory and renal failure. The illness may last from a few days to several weeks, and without treatment, recovery can take months, according to the US Centers for Disease Control and Prevention (CDC).
To reduce the risk of leptospirosis infection, individuals are advised to take several important precautions. According to the CDC, it is essential to avoid wading through dirty rainwater, especially during the rainy season, and to wear gumboots in such conditions.
Proper care of any injuries or cuts is crucial, and frequent handwashing, particularly after handling food or working in potentially contaminated environments, is highly recommended. Additionally, individuals should avoid contact with animals that appear sick or are known carriers of the bacteria.
Vaccination is also vital—pet owners should ensure their pets are vaccinated against leptospirosis, especially if they are frequently exposed to water or wildlife. Staying hydrated by drinking plenty of clean water and preventing water stagnation around the home can further minimize the risk of infection.
© 2024 Bennett, Coleman & Company Limited